Press communication
Lund, Sweden, March 20, 2024
This is a translation of the Swedish press release published 2024-03-20
The initial months of 2024 continue with intensive work and positive progress for Neola Medical in preparation for upcoming studies for market approval and the launch of Neola® in the USA. The human factors validation study with Neola® has commenced as planned in the USA, and the company has been selected to participate in the new scale-up program, 10XHealth. Stanford continues to recognize the company’s lung monitoring product, as it has been chosen as one of ten innovations worldwide to advance to the finals in a competition for direct funding from Stanford. Interest in Neola® remains strong in the USA, and the CEO has been invited to visit a top-ranked neonatal intensive care unit in the USA.
In the spring investor letter, CEO Hanna Sjöström tells more about the human factors validation study with Neola® in the USA, which forms the basis of a part of the study report that will be submitted to the FDA for market approval in the USA. She further elaborates the significance of the new scale-up program, 10XHealth, developed by Smile in close collaboration with Medicon Village, the recent research findings with Neola Medical’s technology published in the Journal of Biomedical Optics, and the increased engagement from Stanford. Additionally, we get insights into CEO Hanna Sjöström’s market preparation activities within the medtech and life science sectors, as well as her visit to the top-ranked neonatal intensive care unit in the USA.
Read the investor letter here: Neola Medical Investor Letter Spring 2024
Read the press release in Swedish here: Neola Medicals CEO berättar mer om de senaste nyheterna i vårens investerarbrev
For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com
Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.